Skip to main content
Evidence Snapshot

Sodium/glucose cotransporter 2

CHEMBL3884 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T11:20:22Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3884
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Sodium/glucose cotransporter 2 as ChEMBL target CHEMBL3884, mapped to UniProt P31639. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Sodium/glucose cotransporter 2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3884
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P31639
Sodium/glucose cotransporter 2
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Sodium/glucose cotransporter 2 matters

As of 2026-09-13

Sodium/glucose cotransporter 2 is reviewed as Sodium/glucose cotransporter 2 (UniProt P31639); Sodium/glucose cotransporter 2 shows approved-linked disease relevance led by type 2 diabetes mellitus. 5 more disease programs remain visible in the same review block.; 15 linked drugs keep this evidence frame grounded.; the current evidence base includes 12 approved drugs, 1766 compounds, and 155 assays, with lead potency reaching pChEMBL 9.5.

Disease context
type 2 diabetes mellitus

Sodium/glucose cotransporter 2 shows approved-linked disease relevance led by type 2 diabetes mellitus. 5 more disease programs remain visible in the same review block. 15 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include BEXAGLIFLOZIN, CANAGLIFLOZIN, DAPAGLIFLOZIN.

Start review with type 2 diabetes mellitus because it currently carries approved-linked support. Linked drugs include BEXAGLIFLOZIN, CANAGLIFLOZIN, DAPAGLIFLOZIN, DAPAGLIFLOZIN PROPANEDIOL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 15 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 12 approved drugs, 1766 compounds, and 155 assays for this target. The dominant activity type is IC50. CHEMBL1164052 is the current potency anchor at pChEMBL 9.5.

Use CHEMBL1164052 as the tractability anchor when discussing potency (pChEMBL 9.5).

Activity source · ChEMBL 36 via Core Engine
12 approved pChEMBL 9.5
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Sodium/glucose cotransporter 2 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P31639, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why type 2 diabetes mellitus is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1766
Total Compounds
155
Total Assays
12
Approved Drugs
IC50: 2317.0, KI: 31.0, EC50: 207.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL1164052
 9.5 IC50 —
No preferred name
CHEMBL565781
 9.5 IC50 —
No preferred name
CHEMBL3703868
 9.5 IC50 —
No preferred name
CHEMBL5288495
 9.5 IC50 —
No preferred name
CHEMBL3703920
 9.4 IC50 —

Approved Drugs

Structure Compound First Approval
BEXAGLIFLOZIN
CHEMBL1808388
 2023
SOTAGLIFLOZIN
CHEMBL3039507
 2019
ERTUGLIFLOZIN
CHEMBL1770248
 2017
TOFOGLIFLOZIN ANHYDROUS
CHEMBL2110731
 2014
EMPAGLIFLOZIN
CHEMBL2107830
 2014
IPRAGLIFLOZIN
CHEMBL2018096
 2014
DAPAGLIFLOZIN
CHEMBL429910
 2012
CANAGLIFLOZIN ANHYDROUS
CHEMBL2048484
 2011
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T11:20:22Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3884